Answers are grounded in this paper and cite their sources.
Oncofetal chondroitin sulfate (ofCS) is a broadly expressed cancer-associated glycosaminoglycan that we originally identified through research into placental malaria. We previously demonstrated the therapeutic potential of targeting ofCS in lymphoma and prostate cancer models using the malaria-derived protein VAR2CSA conjugated to a hemiasterlin-based tubulin inhibitor. The recent generation and development of a human monoclonal antibody (C9) that recapitulates the ofCS-binding specificity of VAR2CSA represents a significant step toward the clinical translation of ofCS-targeted therapies. The C9 antibody can be used as a platform for therapeutic modalities targeting ofCS, including antibody-drug conjugates and bispecific antibodies for engagement with different immune effector cells. However, the potential effector function of the C9 antibody by itself has not been investigated. Here, we examine the immune-activating and therapeutic effects in vitro and in vivo in a human melanoma xenograft mouse model. Our findings demonstrate that the anti-tumor effect of unmodified C9 IgG alone is non-significant, whereas Fc afucosylation induces an increase in anti-tumor effect by antibody-dependent cellular cytotoxicity. This modification of immune-activity shows how C9-based therapies can be designed to induce increased Fc-mediated effector functions.
No takes yet. Share an insight, caveat, or question.
Skeltved et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: